HK1166988A1 - Binding member for gm-csf receptor gm-csf - Google Patents

Binding member for gm-csf receptor gm-csf

Info

Publication number
HK1166988A1
HK1166988A1 HK12107633.4A HK12107633A HK1166988A1 HK 1166988 A1 HK1166988 A1 HK 1166988A1 HK 12107633 A HK12107633 A HK 12107633A HK 1166988 A1 HK1166988 A1 HK 1166988A1
Authority
HK
Hong Kong
Prior art keywords
csf
receptor
binding member
binding members
csfr
Prior art date
Application number
HK12107633.4A
Other languages
English (en)
Inventor
Emma Cohen
Ralph Minter
Paula Harrison
Matthew Sleeman
Andrew Nash
Louis Fabri
Original Assignee
Medimmune Ltd
Zenyth Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Zenyth Operations Pty Ltd filed Critical Medimmune Ltd
Publication of HK1166988A1 publication Critical patent/HK1166988A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
HK12107633.4A 2006-03-27 2012-08-02 Binding member for gm-csf receptor gm-csf HK1166988A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78656906P 2006-03-27 2006-03-27

Publications (1)

Publication Number Publication Date
HK1166988A1 true HK1166988A1 (en) 2012-11-16

Family

ID=38293698

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12107633.4A HK1166988A1 (en) 2006-03-27 2012-08-02 Binding member for gm-csf receptor gm-csf
HK12107671.7A HK1166989A1 (en) 2006-03-27 2012-08-03 Binding member for gm-csf receptor gm-csf

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12107671.7A HK1166989A1 (en) 2006-03-27 2012-08-03 Binding member for gm-csf receptor gm-csf

Country Status (16)

Country Link
US (8) US8506960B2 (sl)
EP (3) EP1999152B1 (sl)
JP (2) JP5335662B2 (sl)
KR (2) KR101451546B1 (sl)
CN (3) CN101443360B (sl)
BR (1) BRPI0709259B1 (sl)
CA (1) CA2647449C (sl)
DK (3) DK1999152T3 (sl)
ES (3) ES2395839T3 (sl)
HK (2) HK1166988A1 (sl)
MX (2) MX348827B (sl)
PL (3) PL2423229T3 (sl)
PT (3) PT2423230E (sl)
RU (2) RU2495050C2 (sl)
SI (3) SI1999152T1 (sl)
WO (1) WO2007110631A1 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1999152T3 (da) * 2006-03-27 2013-01-14 Medimmune Ltd Bindende element til gm-csf-receptor
ES2432173T3 (es) 2006-11-21 2013-12-02 Kalobios Pharmaceuticals, Inc. Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF
JP5608635B2 (ja) * 2008-04-07 2014-10-15 カロバイオス ファーマシューティカルズ インコーポレイティッド 心不全処置のためのｇｍ−ｃｓｆの中和方法
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
US9243061B2 (en) * 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
CN102256621B (zh) 2008-12-22 2017-12-12 墨尔本大学 疼痛治疗
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
CA2760755A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
US20120165220A1 (en) * 2009-09-03 2012-06-28 Colgan Sean P Uses of CD116 Expression Level
EP2766394B1 (en) 2011-10-10 2017-11-22 Medimmune Limited Treatment for rheumatoid arthritis
CA2856329A1 (en) * 2011-11-17 2013-05-23 Nencki Institute Of Experimental Biology Compositions and methods for treating glioma
EP2602264A1 (en) * 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
US9861688B2 (en) * 2012-12-14 2018-01-09 Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz T cell receptors with MHC independent binding to GM-CSF receptor alpha chain
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
EP3889178A1 (en) 2013-08-30 2021-10-06 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
CN106659785B (zh) 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
CA2948944A1 (en) * 2014-05-19 2015-11-26 Medimmune Limited Treatment for rheumatoid arthritis
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
CA3024910A1 (en) 2016-05-24 2017-11-30 Medimmune Limited Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
KR102589598B1 (ko) 2017-03-01 2023-10-13 메디뮨 리미티드 단클론 항체의 제형
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
AU2019377515A1 (en) * 2018-11-09 2021-05-27 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
SG11202105403XA (en) * 2018-11-27 2021-06-29 Staidson Beijing Biopharmaceuticals Co Ltd Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
JP2022535062A (ja) 2019-06-03 2022-08-04 キニクサ ファーマシューティカルズ， リミテッド Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
AU2021401316A1 (en) 2020-12-18 2023-07-06 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
WO2023138499A1 (zh) * 2022-01-20 2023-07-27 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5629283A (en) * 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1991002063A1 (en) * 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2149881A1 (en) * 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
CA2351346C (en) 1998-12-10 2015-09-01 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
KR101143035B1 (ko) * 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
AU2003298187B2 (en) * 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
DK1999152T3 (da) * 2006-03-27 2013-01-14 Medimmune Ltd Bindende element til gm-csf-receptor
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
AU2007231128A1 (en) 2007-10-04
RU2012157042A (ru) 2014-07-10
CN101443360A (zh) 2009-05-27
US20210147559A1 (en) 2021-05-20
MX2008012291A (es) 2009-01-12
PL2423229T3 (pl) 2013-09-30
CA2647449C (en) 2017-05-16
DK2423229T3 (da) 2013-08-05
SI2423230T1 (sl) 2013-09-30
US20190309077A1 (en) 2019-10-10
KR101481844B1 (ko) 2015-01-13
BRPI0709259A2 (pt) 2011-06-28
SI2423229T1 (sl) 2013-09-30
PT1999152E (pt) 2013-01-07
PT2423229E (pt) 2013-08-22
RU2008137763A (ru) 2010-05-10
JP2013121350A (ja) 2013-06-20
WO2007110631A1 (en) 2007-10-04
EP2423230A1 (en) 2012-02-29
BRPI0709259B1 (pt) 2022-05-31
EP2423229B1 (en) 2013-05-08
DK1999152T3 (da) 2013-01-14
RU2639546C2 (ru) 2017-12-21
EP1999152B1 (en) 2012-09-19
DK2423230T3 (da) 2013-08-05
JP5665894B2 (ja) 2015-02-04
ES2424467T3 (es) 2013-10-02
CN103641915A (zh) 2014-03-19
JP2009533020A (ja) 2009-09-17
US20190040145A1 (en) 2019-02-07
KR101451546B1 (ko) 2014-10-16
US20140079708A1 (en) 2014-03-20
MX348827B (es) 2017-06-30
EP2423230B1 (en) 2013-05-08
PT2423230E (pt) 2013-08-26
CN103641915B (zh) 2017-04-12
RU2495050C2 (ru) 2013-10-10
ES2424468T3 (es) 2013-10-02
CN101443360B (zh) 2013-11-27
EP1999152A1 (en) 2008-12-10
CN103641916A (zh) 2014-03-19
US20150376285A1 (en) 2015-12-31
US20120141464A1 (en) 2012-06-07
US20090130093A1 (en) 2009-05-21
JP5335662B2 (ja) 2013-11-06
EP2423229A1 (en) 2012-02-29
CA2647449A1 (en) 2007-10-04
US8506960B2 (en) 2013-08-13
SI1999152T1 (sl) 2013-02-28
US9085628B2 (en) 2015-07-21
PL2423230T3 (pl) 2013-10-31
KR20080113262A (ko) 2008-12-29
KR20130140186A (ko) 2013-12-23
US8263075B2 (en) 2012-09-11
PL1999152T3 (pl) 2013-05-31
ES2395839T3 (es) 2013-02-15
HK1166989A1 (en) 2012-11-16
US20240124596A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
HK1166989A1 (en) Binding member for gm-csf receptor gm-csf
EP2468774A3 (en) Antibody neutralizers of human granulocyte macrophage colony stimulating factor
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
HK1185895A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r il-22 il-22r
EP2572734A3 (en) Cytokine-based fusion proteins for treatment of immune disorders
WO2010011944A3 (en) Protein screeing methods
ZA200902460B (en) Antibody molecules which bind IL-17A and IL-17F
EP2604628A3 (en) Binding members for interleukin-4 receptor alpha (IL-4R) - 173
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
EP1955458A4 (en) SOCIAL AND INTERACTIVE APPLICATIONS FOR MASS MEDIA
HRP20130400T1 (en) Anti-il-23 antibodies, compositions, methods and uses
NO344992B1 (no) Anti-GM-CSF antistoffer og anvendelser for disse
EP2311880A3 (en) Cripto binding molecules
EP2327423A3 (en) Human antibodies against human interleukin-22 (IL-22)
MX2009003774A (es) Anticuerpos para linfotoxina-alfa.
TW200700726A (en) Autoantibody detection for cancer diagnostics
IL177825A0 (en) Natural igm antibodies and inhibitors thereof
CY1114297T1 (el) Μελος προσδεσης για gm-csf υποδοχεα
AU2016202280A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
EP1969008A4 (en) ANTIBODIES TO INTERLEUKIN-22 BINDING PROTEIN AND ITS APPLICATIONS IN THE TREATMENT OF METABOLISM DISORDERS
HUE039022T2 (hu) Interleukin-13-antitest-készítmény